ABSTRACT
Highly specific T-cell responses play key roles in pathogen clearance and maintaining immunologic memory. Next-generation sequencing of the T-cell receptor (TCR) repertoire is an emerging diagnostic technology that capitalizes on the specificity of T-cell responses to probe pathogen exposure. The spirochete Borrelia burgdorferi (Bb) wields an array of antigens with dynamic and complex immunogenic potential, and application of TCR immunosequencing to characterize Bb infection presents opportunities to improve detection of early Lyme disease (LD). By immunosequencing TCR repertoires in blood samples from 3 independent cohorts of patients with early LD and controls from Lyme-endemic/non-endemic regions, we identified 251 public, LD-associated TCRs. These TCRs were used to train a classifier for detection of early LD. The classifier identified LD with 99% specificity and showed 1.9-fold higher sensitivity (56% vs 30%) compared with standard two-tiered testing (STTT). TCR positivity predicted subsequent seroconversion in 37% of STTT-negative patients, suggesting that the T-cell response is detectable before the humoral response. Higher TCR scores were associated with clinical measures of disease severity, including abnormal liver function tests, disseminated rash, and number of symptoms. A subset of LD-associated TCRs mapped to Bb antigens, supporting specificity of this approach. These results suggest that TCR testing may be a highly specific and sensitive approach for identifying LD, particularly in the initial days of illness.
Competing Interest Statement
The authors declare a conflict of interest. M.P., J.N.D., D.B.G., R.M.G., T.M.S., and I.M.K. declare current or former employment with and equity ownership in Adaptive Biotechnologies. S.C.D. declares former employment with Adaptive Biotechnologies, employment with Stanford University School of Medicine, and equity ownership in Adaptive Biotechnologies. A.W.R. declares institutional support from the Steven and Alexandra Cohen Foundation and Global Lyme Alliance. M.J.S. declares institutional support from the Steven and Alexandra Cohen Foundation and National Institutes of Health grant P30 AR070254. E.J.H. declares compensation from the Lyme Disease Biobank and institutional support from Bay Area Lyme Foundation, Steven and Alexandra Cohen Foundation, and Adaptive Biotechnologies. R.O.E. and T.M. declare employment with Adaptive Biotechnologies during the time of this research. L.B. and H.S.R. declare employment with, equity ownership in, and leadership for Adaptive Biotechnologies. J.N.A. declares consulting with Tarsus Pharmaceuticals and Pfizer; participation in an advisory board with Adaptive Biotechnologies; expert testimony; membership in the Bay Area Lyme Foundation Scientific Advisory Board; Past Chair, 2018, HHS Tick-borne Disease Working Group, Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary of Health, Department of Health and Human Services; and institutional support from the Steven and Alexandra Cohen Foundation and Global Lyme Alliance. J.G., E.M., and J.M.C. declare employment with and equity ownership in Microsoft.
Funding Statement
Funding for this study was provided by Adaptive Biotechnologies. Institutional support was provided by the Steven and Alexandra Cohen Foundation (A.W.R., M.J.S., E.J.H., J.N.A.), Global Lyme Alliance (A.W.R., J.N.A.), National Institutes of Health grant P30 AR070254 (M.J.S.), and Bay Area Lyme Foundation (E.J.H.). Medical writing and editorial support were provided by Melanie Styers and Rachel Salmon of BluPrint Oncology Concepts and Kristin MacIntosh and Shahin Shafiani of Adaptive Biotechnologies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures involving human participants were conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. For the LDB cohort, institutional review board (IRB) approval was obtained for each site through the LDB sponsor protocol (Advarra IRB) or the institution-specific IRB. For the Boca cohort, IRB approval was obtained through the Advarra IRB. Human subject protocols for the JHU cohort were approved by the IRBs of Johns Hopkins University and Stanford University. All participants provided written informed consent prior to enrollment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The authors declare a conflict of interest. M.P., J.N.D., D.B.G., R.M.G., T.M.S., and I.M.K. declare current or former employment with and equity ownership in Adaptive Biotechnologies. S.C.D. declares former employment with Adaptive Biotechnologies, employment with Stanford University School of Medicine, and equity ownership in Adaptive Biotechnologies. A.W.R. declares institutional support from the Steven and Alexandra Cohen Foundation and Global Lyme Alliance. M.J.S. declares institutional support from the Steven and Alexandra Cohen Foundation and National Institutes of Health grant P30 AR070254. E.J.H. declares compensation from the Lyme Disease Biobank and institutional support from Bay Area Lyme Foundation, Steven and Alexandra Cohen Foundation, and Adaptive Biotechnologies. R.O.E. and T.M. declare employment with Adaptive Biotechnologies during the time of this research. L.B. and H.S.R. declare employment with, equity ownership in, and leadership for Adaptive Biotechnologies. J.N.A. declares consulting with Tarsus Pharmaceuticals and Pfizer; participation in an advisory board with Adaptive Biotechnologies; expert testimony; membership in the Bay Area Lyme Foundation Scientific Advisory Board; Past Chair, 2018, HHS Tick-borne Disease Working Group, Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary of Health, Department of Health and Human Services; and institutional support from the Steven and Alexandra Cohen Foundation and Global Lyme Alliance. J.G., E.M., and J.M.C. declare employment with and equity ownership in Microsoft.
Order of the figures and tables and references have been updated to reflect edits made to clarify and streamline the text. Figure 1 has been updated, including an addition of a new panel, and new Figures 2E and S2 have been added. Table S1 has been updated and split into Tables 1 and 2. The previous Table S1 was deleted. Figure legends have been updated for clarity in main text and Supplement. Author affiliations have been updated.
Data Availability
Data requests may be submitted for consideration to Adaptive Biotechnologies Medical Information (https://www.adaptivebiotech.com/medical-information-request/).
